Risk factors for acute bilirubin encephalopathy on admission to two Myanmar national paediatric hospitals by unknown
RESEARCH Open Access
Risk factors for acute bilirubin
encephalopathy on admission to two
Myanmar national paediatric hospitals
G. Arnolda1,2* , H. M. Nwe3, D. Trevisanuto4,5, A. A. Thin6, A. A. Thein7, T. Defechereux8, D. Kumara1 and L. Moccia1,4
Abstract
Background: Jaundice is the commonest neonatal ailment requiring treatment. Untreated, it can lead to acute
bilirubin encephalopathy (ABE), chronic bilirubin encephalopathy (CBE) or death. ABE and CBE have been largely
eliminated in industrialised countries, but remain a problem of largely undocumented scale in low resource
settings.
As part of a quality-improvement intervention in the Neonatal Care Units of two paediatric referral hospitals in
Myanmar, hospitals collected de-identified data on each neonate treated on new phototherapy machines over 13–20
months. The information collected included: diagnosis of ABE at hospital presentation; general characteristics such as
place of birth, source of referral, and sex; and a selection of suspected causes of jaundice including prematurity,
infection, G6PD status, ABO and Rh incompatibility. This information was analysed to identify risk factors for hospital
presentation with ABE, using multiple logistic regression.
Results: Data on 251 neonates was recorded over 20 months in Hospital A, and 339 neonates over 13 months in
Hospital B; the number of outborn neonates presenting with ABE was 32 (12.7 %) and 72 (21.2 %) respectively. In the
merged dataset the final multivariate model identified the following independent risk and protective factors:
home birth, ORadj = 2.3 (95 % CI: 1.04-5.4); self-referral, ORadj = 2.6 (95 % CI: 1.2-6.0); prematurity, ORadj = 0.40
(95 % CI: 0.18-0.85); and a significant interaction between hospital and screening status because screening positive for
G6PD deficiency was a strong and significant risk factor at Hospital B (ORadj = 5.9; 95 % CI: 3.0-11.6), but not Hospital A
(ORadj = 1.1; 95 % CI: 0.5-2.5).
Conclusion: The study identifies home birth, self-referral and G6PD screening status as important risk factors for
presentation with ABE; prematurity was protective, but this is interpreted as an artefact of the study design. As
operational research, there is likely to be substantial measurement error in the risk factor data, suggesting that the
identified risk factor estimates are robust. Additional interventions are required to ensure prompt referral of jaundiced
neonates to treatment facilities, with particular focus on home births and communities with high rates of G6PD
deficiency.
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Background
High levels of unconjugated bilirubin in the neonate can
lead to the development of acute bilirubin encephalopathy
(ABE) which first presents as lethargy, hypotonia and poor
sucking. If untreated this can proceed to hypertonia mani-
fested as backward arching of the neck and back (retrocol-
lis and opisthotonos), and ultimately to apnoea, coma and
death [1]. The long term sequelae of bilirubin toxicity,
termed chronic bilirubin encephalopathy (CBE), previously
‘kernicterus’ [2], is characterised by a combination of ab-
normal motor control, movements and muscle tone, dis-
turbed auditory processing, impairment of upward vertical
gaze, and dysplasia of the enamel of deciduous teeth [3].
In high resource settings, the incidence of CBE de-
creased markedly with the introduction of double volume
blood exchange transfusion in the 1940s [4]. The need for
exchange transfusion, in turn, has been reduced by the
use of phototherapy [5], post-partum administration of
anti-D immune globulin G to Rh(D) negative mothers ex-
posed to an Rh(D) positive fetus to prevent maternal Rh
(D) alloimunisation that can lead to neonatal haemolytic
disease in future pregnancies [6], or immunoglobulin dir-
ectly to the newborn as treatment for Rh (D) or ABO
haemolytic disorders [7].
A variety of estimates of the incidence of CBE in high re-
source settings suggest that the incidence in the early
twenty-first century ranges from 1.0-3.7 per 100,000 live
births [8]. The incidence increases with Total Serum Biliru-
bin [TSB]; of neonates with TSB >428 μmol/L, about 6 %
develop CBE, while of neonates with TSB >513 μmol/L,
around 14 % develop CBE [8].
In low resource settings, information about the actual
incidence of ABE and CBE is sparse. A population esti-
mate is available in a survey of 16,979 people <20 years
old in Kolkata, India, which found a prevalence of cere-
bral palsy [CP] of 283/100,000, with 16.7 % of the CP as-
sociated with a history of ‘profound jaundice’ (i.e., 47
cases of jaundice-related CP per 100,000 live births) [9];
this prevalence of jaundice-related CP is an underesti-
mate of the actual incidence of CBE to the extent that
there is excess mortality among children and young
people with jaundice-related CP. A separate population
estimate derived from a four-month study in a single
Baghdad hospital, estimated an incidence of ABE of
1,749/100,000 live births, during a period of severe
health system disruption in 2007–08 [10].
Despite our lack of detailed understanding of the
mechanism for bilirubin neurotoxicity, experience in
industrialised countries makes clear that we have sufficient
knowledge and technical capacity to virtually eliminate
CBE. A systems-based approach has been recommended
in high resource settings, incorporating individual risk as-
sessment and/or pre-discharge TSB, lactation support,
close-follow up in the community, and prompt and
effective intervention when needed [11]. Improving sys-
tems of care in low-resource settings, along similar lines,
is feasible.
The data presented in this report were collected in the
course of a pilot project to improve care in the Neonatal
Care Units (NCUs) at two specialist paediatric referral hos-
pitals in Myanmar. As neonatal jaundice was the most
common reason for admission to the target NCUs, and to
other NCUs not included in the pilot project, we under-
took to collect relevant information as part of program im-
plementation, to better understand the clinical spectrum of
jaundiced neonates at admission, to guide project enhance-
ment in the target hospitals, and to inform the future dir-
ection of jaundice prevention and treatment programs in
Myanmar. These data, while primarily collected for the
purpose of planning and project evaluation, were retro-
spectively examined to identify pre-admission risk factors
for admission to hospital with ABE.
Methods
Setting and context
This study was conducted as part of an intervention at
two tertiary paediatric referral hospitals in Yangon and
Mandalay, Myanmar, hereafter referred to as Hospitals
A and B. We chose these institutions because, in late
2011, they were the two most significant national level
tertiary paediatric referral hospitals in Myanmar; neither
hospital provided birthing facilities, but both had a NCU
for neonatal admissions. The data reported here were
initially collected for a separate purpose – to monitor
and evaluate the intervention. In the current study, we
have used that data opportunistically, to identify risk fac-
tors for ABE at hospital admission and to guide the de-
sign of research and future interventions to encourage
earlier hospital presentation of neonates at risk of ABE.
Ethical approval
Data were collected in the process of routine care
provision. De-identified data were originally collected
for operational purposes, but once a decision to publish
was made, retrospective ethics clearance was sought
from the Ethical Committee on Medical Research in-
volving Human Subjects, Myanmar Department of Health
[approval #14/2014].
Data collection
During the training, both hospitals agreed to collect data
on each neonate treated on the LED phototherapy ma-
chines donated as part of the intervention, and partici-
pated in the specification of the data items for an LED
Phototherapy Treatment Register (LPTR). Hospitals were
not required to collect information on neonates treated
exclusively with conventional fluorescent light photother-
apy machines. While the data elements were prospectively
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defined, we decided to explore risk factors for presentation
with ABE retrospectively, so the study is best described as
a retrospective cohort.
Individual patient information collected in the LPTR
included the following variables: hospital name; date of
birth; gender; gestational age; admission weight; place of
birth (home/health facility); source of referral (self/health
facility); signs of kernicterus, the term routinely used in
Myanmar to describe both ABE and CBE, at admission,
classified as ABE (Yes/No); previous sibling had received
phototherapy (Yes/No); significant bruising (Yes/No);
breastfeeding + feeding poorly (Yes/No); other suspected
cause of jaundice (sepsis/G6PD/ABO/Rh D/Other/Not
stated; multiple selections permitted); date started photo-
therapy on LED machine; TSB at start of phototherapy;
TSB prior to exchange transfusion; and discharge status
(discharged [with or without ‘kernicterus’]/removed by
family/transferred/died).
TSB readings were performed in the hospital laboratory
at Hospital A. At Hospital B, the overwhelming majority of
readings were performed in the NCU on a desktop Biliru-
binometer with a maximum of 513 μmol/L; some readings
were performed in the hospital laboratory, but we did not
record which tests were performed in which location.
At both facilities, G6PD screening was performed using
the qualitative methaemoglobin reduction test. Although
G6PD deficiency is an X-linked genetic disorder, both hos-
pitals screen all neonates admitted for treatment of jaun-
dice, not just males. At the time of the study, families
were expected to pay for the test, but hospitals paid if
families could not; clinicians are therefore confident that
the vast majority of eligible neonates were screened. While
this G6PD screening test is adequate in most situations, it
is known to produce false-negative results in neonates
with low to moderate levels of G6PD deficiency who are
haemolysing, so the test must be repeated 2–4 weeks later
to determine actual G6PD deficiency status in neonates
who screen negative [12]; delayed repeat testing of screen-
negative neonates was not performed at either hospital.
The recording of (suspected) infection/sepsis as a
cause of jaundice was at the discretion of the clinician
completing the LPTR, and was not subject to pre-agreed
diagnostic rules (e.g., laboratory confirmation).
At both facilities, gestation was usually reported as
‘post-term’,’term’, ‘preterm’ or sometimes as a specified
gestational week or range of weeks. The recorded data
was used to classify neonates as ‘Term’ (≥37 weeks’) or
‘Preterm’ (<37 weeks’); where a range of weeks was re-
corded (e.g., “36-38 weeks’”), classification was based on
the midpoint (e.g., 37 weeks’).
Analysis
In the first stage of analysis, we simply described the
characteristics of the treated neonates in each of the
hospitals, with no statistical testing performed. The sec-
ond stage compared characteristics of two sub-groups of
neonates’ treated for jaundice: those presenting with
ABE, and those not recorded as having ABE at hospital
admission. The statistical significance of the difference
in proportions was assessed using Fisher’s Exact Test for
categorical variables, and the Kruskal-Wallis test for a
difference in medians in continuous variables. These
comparison were performed separately for each hospital.
In the final stage of analysis, we aggregated data from
the two hospitals and used multiple logistic regression to
assess the joint effect of multiple risk factors, restricted
to variables that were not considered to be intervening
variables; TSB at presentation and poor feeding at pres-
entation were both excluded for this reason. The analysis
followed a pre-specified modelling strategy: [13] all vari-
ables statistically significant at p < 0.20 in univariate
models were screened in the multivariate model and
retained if significant at p = 0.05; first order interaction
terms between significant main effects were assessed
and retained if statistically significant; and the fit of the
final model was assessed using the area under the ROC
curve (‘c-statistic’) and the Hosmer-Lemeshow Goodness
of Fit test. Analysis was undertaken in SAS v9.4.
Results
Individual patient data was collected for 251 neonates
treated on LED phototherapy machines, over 20 con-
secutive months, at Hospital A (from December 2011 to
July 2013, inclusive), and for 339 neonates treated over
13 non-consecutive months at Hospital B (from December
2011 to 30 June 2013, but with no data provided for
February 2012, May to July 2012, and for January and
February 2013). The average number of neonates
treated per complete month was 13/month (Interquartile
Range [IQR] of 4–32) at Hospital A, and 30/month (IQR:
11–46) at Hospital B.
Characteristics of treated neonates
Table 1 presents key characteristics of neonates treated
with LED phototherapy. Both hospitals report a slight
preponderance of male patients (57 % at Hospital A vs
59 % at Hospital B). Home birth and self-referral to hos-
pital were not uncommon, affecting around a quarter of
treated patients at each hospital, while phototherapy
prior to hospital admission was relatively rare (11 % at
both hospitals). The hospitals differed in two important
ways: Hospital A had a lower proportion of infants ad-
mitted weighing <2,500 g (27 %) than Hospital B (42 %);
and the reported incidence of ABE at admission was
lower at Hospital A (13 %) than Hospital B (21 %).
Table 2 shows relevant information at the start of photo-
therapy treatment. The median age at the start of photo-
therapy was 3 days (IQR: 2–5 days) at both hospitals, and
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median TSB at the start of phototherapy was also similar
(311 μmol/L at Hospital A vs 325 μmol/L at Hospital B).
Both prematurity and previous sibling treated with photo-
therapy were less common among treated neonates at
Hospital A (15 and 0.4 % respectively) than at Hospital B
(26 and 19 %). Significant bruising was rarely recorded in
both hospitals, while breastfeeding and feeding poorly was
reported in 10 % of treated neonates in Hospital A, but
not reported in Hospital B. Infection was the commonest
suspected cause of jaundice (63 in Hospital A and 54 % in
Hospital B), followed by G6PD deficiency (36 and 17 %)
and ABO incompatibility (17 and 15 %); Rhesus incom-
patibility was rarely recorded (2 and 1 %).
Table 3 shows key outcomes for treated neonates. The
rate of Exchange Transfusion among treated neonates was
high in Hospital A (15 %) and markedly higher in Hospital
B (26 %). Mortality was also high (7 % at Hospital A vs
11 % at Hospital B). At each facility, 5 infants were noted
to have been discharged with CBE, representing around
2 % of treated infants.
Table 1 Characteristics of LED phototherapy patients
Hospital A Hospital B
n = 251 n = 339
Percentage male: n (%)a 142 (56.6 %) 195 (58.9 %)
Place of birth: n (%)
Home: n (%) 78 (31.1 %) 88 (26.0 %)
Hospital/Clinic: n (%) 160 (63.7 %) 237 (69.9 %)
Other/Not stated: n (%) 13 (5.2 %) 14 (4.1 %)
Source of referral: n (%)
Home: n (%) 54 (21.5 %) 90 (26.6 %)
Hospital: n (%) 40 (15.9 %) 212 (62.5 %)
Clinic: n (%) 103 (41.0 %) 12 (3.5 %)
Other/Not stated: n (%) 54 (21.5 %) 25 (7.4 %)
Phototherapy elsewhere,
prior to admission: n (%)
28 (11.2 %) 34 (11.0 %)
Admission weight (g)c:
Median (IQR)
2,800 (2,400-3,200) 2,600 (1,940-3,040)
< 1,000 g: n (%) 2 (0.8 %) 2 (0.6 %)
1,000-1,499 g: n (%) 5 (2.0 %) 29 (8.8 %)
1,500-2,499 g: n (%) 61 (24.5 %) 107 (32.5 %)
2,500 g +: n (%) 181 (72.7 %) 191 (58.1 %)
ABEd noted at admission
No: n (%) 219 (87.3 %) 267 (78.8 %)
Yes: n (%) 32 (12.7 %) 72 (21.2 %)
n number, IQR Interquartile range (25th percentile – 75th percentile)
aGender missing for 8 records at Hospital B
bPhototherapy elsewhere, prior to admission missing for 31 records at Hospital B
cAdmission weight missing for two records at Hospital A, and 10 records at
Hospital B
dThe term ‘kernicterus’ is routinely used in both hospitals – this has been
re-classified as ABE
Table 2 Information available at the start of LED phototherapy
Hospital A Hospital B
n = 251 n = 339
At start of phototherapy
Age (days): Median (IQR) 3.0 (2.0-5.0) 3.0 (2.0-5.0)
TSB (μmol/L)a: Median (IQR) 311 (224–445) 325 (234–473)
Risk factors for hyperbilirubinaemia
Preterm (<37 weeks’)c: n (%) 38 (15.3 %) 85 (25.5 %)
Previous sibling treated: n (%) 1 (0.4 %) 66 (19.5 %)
Significant bruising: n (%) 2 (0.8 %) 9 (2.7 %)
Breastfeeding and feeding
poorly: n (%)
25 (10.0 %) Unclear
Suspected cause (multiple
selections permitted)
Suspected infection: n (%) 158 (63.0 %) 183 (54.0 %)
G6PD deficiencyd: n (%) 91 (36.3 %) 58 (17.1 %)
ABO incompatibility: n (%) 43 (17.1 %) 52 (15.3 %)
Rhesus incompatibility: n (%) 4 (1.6 %) 2 (0.6 %)
Not specified: n (%) 14 (5.6 %) 32 (9.4 %)
n number, IQR Interquartile range (25th percentile – 75th percentile)
aTSB at admission missing for 31 records at Hospital A, and seven records at
Hospital B
cGestation at admission missing for one record at Hospital A, and six records
at Hospital B
dScreening test performed, and assessed as screen positive
Table 3 Outcomes of neonates treated with LED phototherapy
Hospital A Hospital B
n = 251 n = 339
Exchange transfusionsa
n (%) 38 (15.3 %) 88 (26.0 %)
TSB (μmol/L) at ET: Median (IQR)b 474 (416–539) 500 (475–513)
Duration of treatment (days):
Median (IQR)c
2.0 (1.0-2.0) 1.0 (1.0-2.0)
Discharge status
Discharged: n (%) 221 (88.1 %) 276 (81.4 %)
Removed by family: n (%) 3 (1.2 %) 8 (2.4 %)
Died: n (%) 18 (7.2 %) 38 (11.2 %)
Transferred to other hospital: n (%) 0 (0.0 %) 2 (0.6 %)
CBEd: n (%) 5 (2.0 %) 5 (1.5 %)
Not stated: n (%) 4 (1.6 %) 10 (3.0 %)
n number, IQR Interquartile range (25th percentile – 75th percentile)
aAt Hospital A, data missing on exchange transfusion status of three records
bTSB at ET missing for 12 transfused neonates at Hospital A and for 42
transfused neonates at Hospital B; note that most readings at Hospital B were
performed on equipment with a maximum reading of 513 μmol/L
cDuration of treatment unavailable for 22 records at Hospital A and 84 records
at Hospital B
d‘Kernicterus’ is the term routinely used in both hospitals; in this situation it is
assumed to refer to CBE
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Comparing characteristics of neonates with and without
ABE at admission
Table 4 compares neonates presenting with and without
ABE for age at admission to hospital and TSB at admis-
sion. At both hospitals, neonates admitted with ABE had
a statistically significantly higher median TSB at admis-
sion (694 vs 291 μmol/L at Hospital A, and 496 vs
287 μmol/L at Hospital B; both with p < 0.0001). At both
hospitals, the median age of neonates admitted with
ABE was 4 days, in comparison to 3 days for jaundiced
neonates admitted without ABE (p = 0.27 at Hospital A,
and p = 0.10 at Hospital B).
Table 5 shows the discharge status of neonates with
and without ABE at admission. ABE at hospital presen-
tation was the key predictor of poor outcome at both
hospitals. At Hospital A, 15 of 32 (47 %) neonates with
ABE at presentation died, and an additional five (16 %)
survived with CBE; this compares to three deaths and
no CBE at discharge among the 219 neonates who did
not have ABE at admission (1.4 %). At Hospital B, 18 of
72 neonates (25 %) admitted with ABE died, and an add-
itional 5 neonates (7 %) survived with kernicterus; this
compares to 20 deaths (7 %) and no survivors with ker-
nicterus among neonates admitted without ABE.
Table 5 also compares neonates with and without ABE
at admission for a variety of risk factors for jaundice,
and suspected causes of jaundice. At Hospital A, the
only statistically significant univariate risk factors for
presentation with ABE were home birth and direct refer-
ral from home (both p < 0.0001). At Hospital B, home
birth and self-referral were again significant, and screen-
ing positive for G6PD deficiency was also a risk, while
preterm birth was protective (p < 0.0001 for all factors).
Multivariate regression model
In the merged dataset the final multivariate model (n = 582
after exclusion of 8 records without data on prematurity)
identified the following independent risk and protective
factors: home birth, ORadj = 2.3 (95 % CI: 1.04-5.4); self-re-
ferral, ORadj = 2.6 (95 % CI: 1.2-6.0); prematurity,
ORadj = 0.40 (95 % CI: 0.18-0.85); and a significant inter-
action between hospital and screening status because
screening positive for G6PD deficiency was a strong and
significant risk factor at Hospital B (ORadj = 5.9; 95 % CI:
3.0-11.6), but not at Hospital A (ORadj = 1.1; 95 % CI: 0.5-
2.5).
Discussion
In 2002, the American National Quality Forum defined
“Death or serious disability (kernicterus) associated with
failure to identify and treat hyperbilirubinemia in neo-
nates” as a serious reportable event [14], reflecting its
belief that kernicterus should be a ‘never-event’ that can
be entirely avoided. The weak systems of perinatal care
that are typical in low resource settings, however, create
additional challenges on the path to making kernicterus
a ‘never-event’. The reality in low resource settings is
that neonates frequently arrive in paediatric emergency
rooms with signs of ABE. Numerous studies have dem-
onstrated higher risks of ABE or kernicterus among out-
born neonates in low resource settings [15–18]; the
current study seeks to add to this, by identifying specific
risk factors which lead to these outborn neonates being
admitted with established signs of ABE.
Risks and protective factors for admission with ABE in the
current study
Home-birth or self-referral
Home born and self-referred neonates are substantially
overlapping groups, with 80 % of home births and only
3 % of facility births being self-referred, so it was surpris-
ing that both were retained in the final model. We are
aware of one study that examined home birth and found
no study reporting on self-referral as risk factors for pres-
entation with ABE: a Baghdad study during a period of se-
vere health system disruption found that home birth was
not a significant risk factor for CBE or death (OR = 1.2;
95 % CI: 0.6-2.5); the study did not report risk of ABE at
presentation [10].
It is unclear that something intrinsic to place of birth
would make urban or peri-urban home birth a risk factor
for presentation with ABE, so it seems more plausible that
home birth is a proxy for other factors. Plausible factors
include: characteristics of mothers that give birth at home
(e.g., racial differences correlated with both genetic risk
and socio-economic status); characteristics of the
Table 4 Age and TSB at admission of neonates with and without ABE at admission
Hospital A Hospital B
ABE at admission
(n = 32)
No ABE at admission
(n = 219)
p-value ABE at admission
(n = 72)
No ABE at admission
(n = 267)
p-value
n Median [IQR] n Median [IQR] n Median [IQR] n Median [IQR]
Age at start of phototherapy (days) 32 4.0 (2.0-5.0) 219 3.0 (2.0-5.0) 0.27 72 4.0 (2.0-5.5) 267 3.0 (2.0-5.0) 0.10
Total serum bilirubin at admissiona(μmol/L) 28 694 (581–795) 192 291 (211–401) <0.0001 69 496 (475–513) 263 287 (210–393) <0.0001
n number, IQR Interquartile range (25th percentile – 75th percentile)
aThe majority of readings at Hospital B were performed on equipment with a maximum reading of 513 μmol/L
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accoucher (e.g., Traditional Birth Attendants vs midwives)
and/or characteristics of the quality of care (e.g., high rates
of asphyxia, lower rates of provision of high quality post-
partum education about signs requiring referral to hos-
pital); characteristics of the post-partum follow-up (e.g.,
less frequent follow-up of home births); and persistence of
barriers to facility access for both delivery and care of
the sick neonate (e.g., physical, attitudinal, or finan-
cial). Self-referral, on the other hand, may be a proxy
for inaccessibility of facility-based care and/or delayed
access for other reasons. The fact that both factors
remain significant in the final model, despite substantial
overlap, suggests a complex interplay of factors resulting
in late presentation.
While it is clear from the prevalence of ABE at admis-
sion that late presentation is important, it is not clear
from our data that age at start of phototherapy is associ-
ated with ABE at presentation. Age at presentation was
measured crudely in the current study (in days rather
than hours, for practical reasons) and that this intro-
duced random error which results in a bias towards sta-
tistically non-significant findings, despite the fact that
neonates with ABE presented at a median of 4 days,
compared to a median of 3 days for neonates without
ABE. It is plausible that ‘late’ presentation may need to
be defined in terms of disease progression, as well as in
chronological terms.
G6PD deficiency
G6PD deficiency has been identified as suspected cause
of ABE at admission in about a third of the babies in
two Nigerian case series of neonates with ABE [15, 19],
slightly lower than the rate found in neonates with ABE
at Hospitals A and B (44 and 40 % respectively). The
prevalence of G6PD deficiency in Myanmar is estimated
at 6.1 % [20], somewhat higher than the median of
3.95 % (IQR: 3.4 %- 7.9 %) in 184 countries for which
there are estimates [21], but substantially lower than the
16.9 % estimated in Nigeria [20]. On the face of it, one
would therefore expect Nigerian studies to have a higher
prevalence of neonates with ABE that screen positive for
G6PD deficiency. A separate Nigerian case control study
found that 67-75 % of neonates with ABE screened posi-
tive for G6PD deficiency, in comparison to only 17-22 %
of neonates without ABE (range provided as some neo-
nates not screened) [18]. In the current study, G6PD de-
ficiency was only a risk factor for ABE at Hospital B
(40 % in neonates with ABE vs 11 % in neonates without
ABE). It is unclear why G6PD deficiency was not a risk
factor in Hospital A: Hospital A had a higher overall rate
of G6PD deficiency (36 % vs 17 % in Hospital B) and a
lower overall rate of ABE at presentation (13 % vs 21 %);
one possibility is that there are differences in the distri-
bution of local genetic variants causing G6PD deficiency
which are in turn related to the incidence of ABE.
Table 5 Selected characteristics and outcomes of neonates with and without ABE at admission














n % n % n % n %
Demographic Malea 17 53.1 125 57.1 0.71 45 62.5 150 57.9 0.50
Home birth 22 68.8 56 25.6 <0.0001 38 52.8 50 18.7 <0.0001
Referred from home 16 50.0 38 17.4 0.0001 40 55.6 50 18.7 <0.0001
Selected risk factors for hyperbilirubinaemia Preterm (<37 weeks’)b 3 9.4 35 16.1 0.43 6 8.3 79 30.3 <0.0001
Previous sibling 0 0.0 1 0.5 1.0 15 20.8 51 19.1 0.74
Significant bruising 1 3.1 1 0.5 0.24 3 4.2 6 2.3 0.41
Previous phototherapy 2 6.3 26 11.9 0.55 9 12.5 25 10.6 0.67
Suspected cause (multiple selections permitted) Suspected infection 23 71.9 135 61.6 0.32 34 47.2 149 55.8 0.23
G6PD deficiencyc 14 43.8 77 35.2 0.43 29 40.3 29 10.9 <0.0001
ABO incompatibility 3 9.4 40 18.3 0.31 8 11.1 44 16.5 0.36
Rhesus incompatibility 0 0.0 4 1.8 1.0 0 0.0 2 0.8 1.0
Other/Not specified 3 9.4 11 5.0 0.40 4 5.6 28 10.5 0.26
Discharge Status Died 15 46.9 3 1.4 <0.0001 18 25.0 20 7.5 <0.0001
Lived, with ABE 5 15.6 0 0.0 5 6.9 0 0.0
All other discharge 12 37.5 216 98.6 49 68.1 247 92.5
n number, IQR Interquartile range (25th percentile – 75th percentile)
aGender missing for 8 records at Hospital B (none of whom had ABE at presentation)
bGestation missing for two records at Hospital A, and six records at Hospital B (none of the eight had ABE at presentation)
cScreening test performed, and assessed as screen positive
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Prematurity
Several facility-based studies have noted that premature or
low birth weight babies have lower rates of ABE at presen-
tation: a Nigerian study found that 14 % of cases with
ABE weighed <2,500 g in comparison to 37 % of controls
admitted to the nursery for any reason (p = 0.01) [15]; a
separate Nigerian study found that 22 % of cases with
ABE weighted ≤2,500 g, in comparison to 42 % of clinic-
ally jaundiced neonates admitted to the nursery (p = 0.46)
[18]; and a Bangladeshi study found that 11 % of neonates
that presented with or developed ABE during the study
were preterm, in comparison to 21 % of neonates admit-
ted to the nursery with jaundice or who developed jaun-
dice during their stay (p = 0.55) [22].
Conversely, low gestation has long been identified as an
epidemiological risk factor for kernicterus. For example, a
classic 1950–54 study estimated the incidence of kernic-
terus by gestation among neonates admitted to the new-
born units and surviving to 48 h: ≤30 weeks 10,100/
100,000 admitted survivors; 31–32 weeks 5,700/100,000;
33–34 weeks 3,200/100,000; 35–36 weeks 1,100/100,000;
and ≥37 weeks 800/100,000 admitted survivors [23].
Given this long established risk-factor status, the apparent
protective role of low gestation found in the current study,
and in the other studies reported above, is interpreted as
an artefact arising from the use of controls admitted to
the neonatal nursery. The term neonates in these studies
are drawn from a pool at extremely high risk of ABE,
whereas the preterm neonates are all likely to be routinely
admitted and often receive prophylactic phototherapy,
simultaneously preventing the development of ABE.
Other risk factors for ABE
Rh (D) isoimmunisation
The incidence of kernicterus in Greece prior to the
introduction of exchange transfusion or phototherapy
has been estimated at 40/100,000 live births among neo-
nates affected by Rh haemolytic disease [24], while a re-
cent modelling study estimated that roughly one third of
ABE cases were caused by Rh disease [21]. In Myanmar,
the prevalence of Rh negative blood group prevalence is
estimated at 0.8 %, substantially lower than the median
of 3.7 % (IQR: 3.5 %-10.0 %) for 138 countries with a
neonatal mortality rate above 5/1,000 live births [21].
This low prevalence in Myanmar results in few neonates
with ABE due to Rh (D) incompatibility, despite the lack
of systematic screening and prophylaxis to prevent Rh
(D) isoimmunisation.
Sepsis
It has been noted that sepsis can increase the risk of se-
vere hyperbilirubinaemia and or bilirubin neurotoxicity
by altering the binding affinity of albumin [25], and that
sepsis can result in acute, severe hyperbilirubinaemia
[26]. Investigation of this factor in the current study was
hampered by the lack of a firm definition, or laboratory
confirmation. At Hospital A, 63 % of treated neonates had
‘suspected sepsis’ recorded as a cause while at Hospital B
the figure was slightly lower at 54 %; infection/sepsis was
not a statistically significant predictor of ABE at presenta-
tion in either hospital. The literature on the role of sepsis
as a risk factor for ABE in low resource settings is limited:
a Nigerian study attributed sepsis as the cause of ABE in
43 % of cases but did not give the rate of sepsis in a con-
trol series [15].
Limitations
The current study was conducted as operational re-
search, resulting in a number of limitations. First, the
cohort studied represents neonates treated on LED
phototherapy. Participating clinicians state that most in-
fants were treated on the LED machines, and those that
were not tended to have lower TSB. Any bias is there-
fore likely to be small and, if there is bias, it is likely to
result in a compressed patient spectrum towards higher
risk infants, shrinking risk estimates towards the null.
Second, there were a number of measurement-related
limitations: ABE was not formally defined, but relied on
the clinical judgement of experienced clinicians at each
facility, leaving open the possibility of under- or over-
diagnosis of ABE; age at admission was measured in
days rather than hours; there was no delayed re-test of
neonates that received a negative G6PD screening result;
there were no strict definitions of sepsis as a suspected
cause of jaundice; different hospitals may have different
proclivities to record particular risk factors (e.g., previ-
ous sibling treated with phototherapy and significant
bruising); and the in-unit desktop Bilirubinometer at
Hospital B, used for the majority of TSB readings, was
restricted to an upper limit of 513 μmol/L. All of these
limitations result in misclassification of risk factors for
ABE, or of ABE itself, and this misclassification neces-
sarily results in a bias towards the null (i.e., OR = 1.0).
Care should therefore be taken not to over-interpret
non-significant findings, but statistically significant risk
factors can be considered to be robust estimates, pos-
sibly with the risk factor status diminished due to mis-
classification errors.
Conclusions and next steps
This study demonstrates that home birth and self-referral
to a paediatric hospital and, in one hospital screening
positive for G6PD deficiency, are significant risk factors
for paediatric hospital admission of jaundiced neonates
with ABE in Myanmar. Additional information is required
to identify possible points at which it is feasible to intervene,
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to reduce clinically late presentation of outborn neonates
with ABE.
Prospective case–control studies have been initiated to
identify in more detail the barriers to timely presentation
of jaundiced neonates. Depending on the findings of these
case–control studies, a range of interventions are possible.
Examples of possible interventions include: general infor-
mation for the community (e.g., to ensure that mothballs
are removed from the home environment of neonates to
prevent triggering G6PD deficiency); training and infor-
mation to be distributed by healthcare providers (public
and private) to ensure new mothers and their families can
identify jaundice, and are aware of the need to self-refer
quickly if a baby becomes jaundiced in the first 72 h, or if
severe jaundice appears rapidly at any time thereafter;
home visits by nurses/midwives in the first week of life, in
line with national policy, could be optimally-timed, target-
ing home-births; training of staff at primary healthcare
settings to identify and rapidly transfer babies at risk of ex-
change transfusion, and development of protocols to en-
sure rapid transfer of these neonates; and provision of
TSB testing equipment and high quality phototherapy
equipment to lower level facilities. While the provision of
TSB screening equipment to home visit staff is not cur-
rently feasible due to cost, new systems such as ‘Bilistick’
costing €150 for the prototype and a few cents per test
have been found to be highly accurate [27], raising the
possibility that screening can be undertaken at lower
levels in the health care system.
Given the many demands on health systems in low-
resource settings, it is important to prioritise interventions
with a goal of achieving optimal results from any given re-
source input. The data presented in this report, represent
a first step in the process of identifying the interventions
required to address the mortality and morbidity associated
with ABE in Myanmar, as part of the process of interven-
ing to reduce that mortality and morbidity.
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